≥65岁成人中13价肺炎球菌结合疫苗与23价肺炎球菌多糖疫苗的使用:免疫实践咨询委员会更新建议
美国免疫实践咨询委员会(ACIP)于2019年6月26日投票取消≥65岁成人常规接种13价肺炎球菌结合疫苗(PCV13)的建议,改为对无免疫抑制状况、脑脊液漏或人工耳蜗且未接种过PCV13的≥65岁成人基于共享临床决策接种PCV13;所有≥65岁成人应继续接种1剂23价肺炎球菌多糖疫苗(PPSV23),若决定接种PCV13,应至少早于PPSV23 1年。
要点
- 取消≥65岁成人常规接种PCV13的建议,改为基于共享临床决策。
- 所有≥65岁成人应继续接种1剂PPSV23。
- 若决定接种PCV13,应至少早于PPSV23 1年。
核心结论
- ACIP投票取消≥65岁成人常规使用PCV13的建议,改为基于共享临床决策推荐接种PCV13。
- 所有≥65岁成人应继续接种1剂PPSV23。
- ACIP继续推荐≥19岁有免疫抑制状况、脑脊液漏或人工耳蜗的成人按序接种PCV13与PPSV23。
研究设计与样本
- ACIP于2019年6月26日审查过去3年积累的证据后投票更新建议。
主要发现
- 2014年ACIP基于PCV13对≥65岁成人PCV13型肺炎的安全性和有效性,推荐所有≥65岁成人常规按序使用PCV13与PPSV23。
- ACIP当时预计儿童PCV13接种通过减少疫苗血清型携带和传播(即PCV13间接效应)将持续降低成人疾病负担,因此需要重新评估该建议。
关键数值与推荐
- 对无免疫抑制状况、脑脊液漏或人工耳蜗且未接种过PCV13的≥65岁成人,基于共享临床决策推荐接种PCV13。
- 所有≥65岁成人应继续接种1剂PPSV23。
- 若决定接种PCV13,应至少早于PPSV23 1年。
- ≥19岁有免疫抑制状况、脑脊液漏或人工耳蜗的成人,继续推荐按序接种PCV13与PPSV23。
临床怎么用
- 疫苗提供者与患者进行共享临床决策时,可考虑患者暴露于PCV13血清型的风险及因基础疾病发生肺炎球菌病的风险。
- 部分≥65岁成人可能暴露于PCV13血清型的风险增加,如居住在养老院或其他长期护理机构、居住在儿童PCV13接种率低或前往无儿童PCV13规划地区者,可能从PCV13接种中获得高于平均的获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]). In 2014, the Advisory Committee on Immunization Practices (ACIP)* recommended routine use of PCV13 in series with PPSV23 for all adults aged ≥65 years based on demonstrated PCV13 safety and efficacy against PCV13-type pneumonia among adults aged ≥65 years (1). At that time, ACIP recognized that there would be a need to reevaluate this recommendation because it was anticipated that PCV13 use in children would continue to reduce disease burden among adults through reduced carriage and transmission of vaccine serotypes from vaccinated children (i.e., PCV13 indirect effects). On June 26, 2019, after having reviewed the evidence accrued during the preceding 3 years (https://www.cdc.gov/vaccines/acip/recs/grade/PCV13.html), ACIP voted to remove the recommendation for routine PCV13 use among adults aged ≥65 years and to recommend administration of PCV13 based on shared clinical decision-making for adults aged ≥65 years who do not have an immunocompromising condition,† cerebrospinal fluid (CSF) leak, or cochlear implant, and who have not previously received PCV13. ACIP recognized that some adults aged ≥65 years are potentially at increased risk for exposure to PCV13 serotypes, such as persons residing in nursing homes or other long-term care facilities and persons residing in settings with low pediatric PCV13 uptake or traveling to settings with no pediatric PCV13 program, and might attain higher than average benefit from PCV13 vaccination. When patients and vaccine providers§ engage in shared clinical decision-making for PCV13 use to determine whether PCV13 is right for a particular person, considerations might include both the person's risk for exposure to PCV13 serotypes and their risk for developing pneumococcal disease as a result of underlying medical conditions. All adults aged ≥65 years should continue to receive 1 dose of PPSV23. If the decision is made to administer PCV13, it should be given at least 1 year before PPSV23. ACIP continues to recommend PCV13 in series with PPSV23 for adults aged ≥19 years with an immunocompromising condition, CSF leak, or cochlear implant (2).
引用
- Matanock A, Lee G, Gierke R, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31751323. doi:10.15585/mmwr.mm6846a5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。